Tech entrepreneur Paul Conyngham utilized AI tools, including ChatGPT and AlphaFold, to develop an experimental mRNA vaccine for his rescue dog, Rosie, diagnosed with aggressive mast cell cancer. After undergoing costly veterinary treatments with minimal success, Rosie’s condition improved significantly; her tumour shrank by half post-vaccination, igniting hope for similar human applications. Conyngham, with 17 years in machine learning, sequenced Rosie’s DNA, compared healthy and mutated cells, and collaborated with researchers at the University of New South Wales to analyze genetic data. Expert Martin Smith expressed amazement at Conyngham’s capability in leveraging AI without a biology background. This groundbreaking development showcases the potential of personalized cancer vaccines, raising questions about broader applications in human medicine. As Rosie received her first doses in December, Conyngham is now focused on a second vaccine targeting another untreated tumour, furthering the evolution of personalized cancer immunotherapy.
Source link
Share
Read more